99% USP Duloxetine Hydrochloride Powder CAS 136434 -34-9 Duloxetine HCl
Model NO.
hupharma
Delivery Time
1-3 Days
Shipping
Worldwide
Minimum
10g
Payment
Bitcoin/Wu/Mg/Wire Transfer
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg, 25kg
Trademark
hupharma
Origin
China
HS Code
2937290090
Production Capacity
20000kg Per Month
Reference Price
$ 0.81 - 0.90
Description
Product Description
99% USP Duloxetine hydrochloride Powder CAS 136434-34-9 Duloxetine Hcl
99% USP Duloxetine hydrochloride Powder CAS 136434-34-9 Duloxetine Hcl
99% USP Duloxetine hydrochloride Powder CAS 136434-34-9 Duloxetine Hcl
Product Name: Duloxetine hydrochloride
Synonyms: Duloxetime;LY-248686 HCl;(γS)-N-methyl-γ-(1-naphthalenyloxy)-2-thiophenepropanamine, hydrochloride (1:1);(+)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine hydrochloride;LY-248686 hydrochloride;Duloxetine for system suitability;Duloxetine hydrochloride solution;(S)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine hydrochloride
CAS: 136434-34-9
MF: C18H20ClNOS
MW: 333.88
EINECS: 603-962-5
Appearance: White Crystalled Powder
Shipping: Safety and fast, guarantee delivery
Duloxetine is a selective serotonin (5-HT) and norepinephrine reuptake inhibitor (SSNRI) for oral administration, and it is currently approved in the US and in Europe for the treatment of major depressive disorder (MDD) and diabetic peripheral neuropathic pain (DPN). Additionally, it is indicated for the treatment of stress urinary incontinence (SUI) in Europe. However, the US approval for SUI is still pending, and Lilly recently withdrew the NDA for this indication. It is expected that additional clinical trials may be required to secure FDA approval for SUI treatment due to concern over the potential of duloxetine to prolong the QT interval in patients taking concomitant CYP2D6 or CYP1A2 inhibitors such as tricyclic antidepressants, type 1C antiarrhythmics and phenothiazines. Duloxetine is the second SSNRI to enter the market. Its predecessor, venlafaxine, has been available since 1994 for the treatment of depression. Duloxetine has a higher affinity for human norepinephrine (Ki=7.5 nM) and 5-HT transporters (Ki=0.8 nM) than venlafaxine (Ki=2480nM and 82nM, respectively). Additionally, it shows a more balanced ratio of 5-HT to norepinephrine uptake inhibition than venlafaxine. Duloxetine is a moderate inhibitor of dopamine reuptake (Ki=300nM in rat brain preparations) and shows only weak affinity for muscarinic, α1-and α2 adrenergic and histamine H1 receptors (Ki=>2.3μ). It is devoid of any activity against monoamine oxidase. In vivo, duloxetine inhibits 5-HT and norepinephrine uptake in rats, with ED50 values of 12 mg/kg and 22 mg/kg p.o., respectively, and has no effect on dopamine uptake at doses up to 30 mg/kg. The antidepressant and central paininhibitory action of SSNRIs are derived from the inhibition of both 5-HT and norepinephrine uptake, which increases the availability of neurotransmitters and ultimately increases serotonergic and noradrenergic function within the CNS. In the treatment of SUI with duloxetine, the increased neurotransmitter concentration is believed to increase the tone and contractions of the urethral sphincter at the opening of the bladder, helping to prevent accidental urine leakage. The absolute stereochemistry of duloxetine is shown to be S(+). It is prepared in four steps starting from 2-acetylthiophene. A key intermediate in the synthesis of duloxetine is (S)-3-dimethylamino-1-(2-thienyl)-1-propanol, which is obtained from the corresponding ketone, either by reduction with sodium borohydride and subsequent chiral resolution of the alcohol product with S-mandelic acid, or by enantioselective reduction with a chiral amine complex of lithium aluminum hydride. Etherification of this intermediate with 1-fluoronaphthalene, followed by N-demethylation with trichloroethylchloroformate affords duloxetine. Orally administered duloxetine is well absorbed, with Cmax achieved in 6 hours post dose. It exhibits dose-proportional pharmacokinetics at doses of 20-40 mg twice daily, with an average bioavailability of about 50% and an elimination half-life of about 12 hours. The volume of distribution is high (1943 L) and steady-state plasma levels are achieved after 3 days of dosing. Duloxetine is extensively metabolized, mainly by CYP2D6 and CYP1A2. The primary routes of elimination are in the urine (70%) and in the feces (20%). The recommended dosages of duloxetine are 20 mg to 30 mg twice daily for treating MDD, 60 mg once daily for treating DPN, and 40 mg twice daily for treating SUI. In clinical trials with adult MDD outpatients (n =1059), duloxetine at doses of 40-120 mg daily for 8 to 9 weeks demonstrated superiority over placebo as measured by improvement in the 17-item Hamilton Depression Rating Scale total score. In trials involving 791 DPN patients, 60 and 120 mg once daily dose of duloxetine statistically significantly improved the endpoint mean pain scores from baseline, and increased the proportion of patients with at least 50% reduction in pain score from baseline. All doses of duloxetine resulted in superior results than placebo. In phase III studies of adult women with predominant symptoms of SUI (n=1635), duloxetine 40 mg twice daily reduced the median incontinence episode frequency from baseline to a significantly greater extent than placebo (50.0-53.6% versus 27.5-40.0%). In addition, duloxetine recipients experienced significantly greater increases in their average voiding interval than placebo recipients (15.0-20.4 versus 1.7-8.5 minutes). The most commonly observed adverse events associated with duloxetine therapy are nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating. As with other 5-HT reuptake inhibitors, duloxetine is contraindicated in patients taking MAO inhibitors. Additionally, it is contraindicated in patients with uncontrolled narrowangle glaucoma.
Other products
SARMS powder
Peptides list
99% USP Duloxetine hydrochloride Powder CAS 136434-34-9 Duloxetine Hcl
99% USP Duloxetine hydrochloride Powder CAS 136434-34-9 Duloxetine Hcl
Product Name: Duloxetine hydrochloride
Synonyms: Duloxetime;LY-248686 HCl;(γS)-N-methyl-γ-(1-naphthalenyloxy)-2-thiophenepropanamine, hydrochloride (1:1);(+)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine hydrochloride;LY-248686 hydrochloride;Duloxetine for system suitability;Duloxetine hydrochloride solution;(S)-N-Methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine hydrochloride
CAS: 136434-34-9
MF: C18H20ClNOS
MW: 333.88
EINECS: 603-962-5
Appearance: White Crystalled Powder
Shipping: Safety and fast, guarantee delivery
Duloxetine is a selective serotonin (5-HT) and norepinephrine reuptake inhibitor (SSNRI) for oral administration, and it is currently approved in the US and in Europe for the treatment of major depressive disorder (MDD) and diabetic peripheral neuropathic pain (DPN). Additionally, it is indicated for the treatment of stress urinary incontinence (SUI) in Europe. However, the US approval for SUI is still pending, and Lilly recently withdrew the NDA for this indication. It is expected that additional clinical trials may be required to secure FDA approval for SUI treatment due to concern over the potential of duloxetine to prolong the QT interval in patients taking concomitant CYP2D6 or CYP1A2 inhibitors such as tricyclic antidepressants, type 1C antiarrhythmics and phenothiazines. Duloxetine is the second SSNRI to enter the market. Its predecessor, venlafaxine, has been available since 1994 for the treatment of depression. Duloxetine has a higher affinity for human norepinephrine (Ki=7.5 nM) and 5-HT transporters (Ki=0.8 nM) than venlafaxine (Ki=2480nM and 82nM, respectively). Additionally, it shows a more balanced ratio of 5-HT to norepinephrine uptake inhibition than venlafaxine. Duloxetine is a moderate inhibitor of dopamine reuptake (Ki=300nM in rat brain preparations) and shows only weak affinity for muscarinic, α1-and α2 adrenergic and histamine H1 receptors (Ki=>2.3μ). It is devoid of any activity against monoamine oxidase. In vivo, duloxetine inhibits 5-HT and norepinephrine uptake in rats, with ED50 values of 12 mg/kg and 22 mg/kg p.o., respectively, and has no effect on dopamine uptake at doses up to 30 mg/kg. The antidepressant and central paininhibitory action of SSNRIs are derived from the inhibition of both 5-HT and norepinephrine uptake, which increases the availability of neurotransmitters and ultimately increases serotonergic and noradrenergic function within the CNS. In the treatment of SUI with duloxetine, the increased neurotransmitter concentration is believed to increase the tone and contractions of the urethral sphincter at the opening of the bladder, helping to prevent accidental urine leakage. The absolute stereochemistry of duloxetine is shown to be S(+). It is prepared in four steps starting from 2-acetylthiophene. A key intermediate in the synthesis of duloxetine is (S)-3-dimethylamino-1-(2-thienyl)-1-propanol, which is obtained from the corresponding ketone, either by reduction with sodium borohydride and subsequent chiral resolution of the alcohol product with S-mandelic acid, or by enantioselective reduction with a chiral amine complex of lithium aluminum hydride. Etherification of this intermediate with 1-fluoronaphthalene, followed by N-demethylation with trichloroethylchloroformate affords duloxetine. Orally administered duloxetine is well absorbed, with Cmax achieved in 6 hours post dose. It exhibits dose-proportional pharmacokinetics at doses of 20-40 mg twice daily, with an average bioavailability of about 50% and an elimination half-life of about 12 hours. The volume of distribution is high (1943 L) and steady-state plasma levels are achieved after 3 days of dosing. Duloxetine is extensively metabolized, mainly by CYP2D6 and CYP1A2. The primary routes of elimination are in the urine (70%) and in the feces (20%). The recommended dosages of duloxetine are 20 mg to 30 mg twice daily for treating MDD, 60 mg once daily for treating DPN, and 40 mg twice daily for treating SUI. In clinical trials with adult MDD outpatients (n =1059), duloxetine at doses of 40-120 mg daily for 8 to 9 weeks demonstrated superiority over placebo as measured by improvement in the 17-item Hamilton Depression Rating Scale total score. In trials involving 791 DPN patients, 60 and 120 mg once daily dose of duloxetine statistically significantly improved the endpoint mean pain scores from baseline, and increased the proportion of patients with at least 50% reduction in pain score from baseline. All doses of duloxetine resulted in superior results than placebo. In phase III studies of adult women with predominant symptoms of SUI (n=1635), duloxetine 40 mg twice daily reduced the median incontinence episode frequency from baseline to a significantly greater extent than placebo (50.0-53.6% versus 27.5-40.0%). In addition, duloxetine recipients experienced significantly greater increases in their average voiding interval than placebo recipients (15.0-20.4 versus 1.7-8.5 minutes). The most commonly observed adverse events associated with duloxetine therapy are nausea, dry mouth, constipation, decreased appetite, fatigue, somnolence, and increased sweating. As with other 5-HT reuptake inhibitors, duloxetine is contraindicated in patients taking MAO inhibitors. Additionally, it is contraindicated in patients with uncontrolled narrowangle glaucoma.
Other products
| Product Name | Purity |
| Testoste Enanthat | 99%+ |
| Testoste Cypionat | 99% |
| Testoste Acetat | 99% |
| Testoste Propionat | 99% |
| Testoste Decanoat | 99% |
| Testoste Phenylpropionat | 98%+ |
| Testoste Blend / Sustan250 | 99% |
| Testoste Undecanoat | 99% |
| Testoste Isocaproat | 99% |
| Fluoxymestero / Halotest | 99% |
| Bolde undecanoat / Equipose | 98% |
| Nandr Decanoat / Deca | 99%+ |
| Nandr Phenylpropiona/Deca Durabolin | 99%+ |
| Trenbo Acetat | 99%+ |
| Trenbo Enanthat | 99%+ |
| Trenbo Hexahydrobenzyl carbonate / Parabol | 99% |
| Drostanol Propionat / Master Propionat | 99% |
| Drostanol Enanthat / Master Enanthat | 99% |
| Methenolo Acetat / Primobo Acetat | 99% |
| Methenolo Enanthat / Primobol Enanthat | 99% |
| Oxandro / Anav | 99% |
| Metandien / Diana | 99% |
| Oxymetho / Anadr | 99% |
| Stanoz / winstr | 99% |
| Mestero / Provir | 99% |
| 4-chlorinedehydro-methyl testoste/Turinab | 99% |
| Methyl drostanol / Superdl /Methaste | 99% |
| Clomid | 98% |
| Arimidex | 99% |
| Aromasin | 99% |
| MK-677 | 99%+ |
| MK-2866/Ostarine | 99% |
| Gw501516/Cardarine | 99% |
| Andarine/S-4 | 99% |
| Yk11 | 99% |
| SR9009 | 98%+ |
| SR9011 | 99% |
| Ligandrol/LGD-4033 | 99% |
| RAD 140 | 99% |
| S-23 | 99% |
| Aicar | 99%+ |
| Trenavar | 99%+ |
| Halodrol | 99%+ |
| Epistane | 99%+ |
| Lorcaserin | 99%+ |
| Cetilistat | 99% |
| Orlistat | 99% |
| tadalafil | 99.5% |
| Yohimbine | 98%+ |
| Avanafil | 99% |
| Vardenafil | 99% |
| Benzocaine | 99.5% |
| Lidocaine | 99.5% |
| Procaine Hcl | 99.5% |
| Tetracaine | 99.8% |
| dibucaine | 99.5% |
| Sunfiram | 98%+ |
| Noopept | 98%+ |
| Dextromethorphan Hydrobromide | 98%+ |
| Oxytocin | 99%+ |
| Bimatoprost | 99% |
SARMS powder
| Product Name | Purity | CAS# |
| MK-677 | 99%+ | 159752-10-0 |
| MK-2866/Ostarine | 99% | 1202344-20-9 |
| Gw501516/Cardarine | 99% | 317318-70-0 |
| Andarine/S-4 | 99% | 401900-40-1 |
| Yk11 | 99% | 431579-34-9 |
| SR9009 | 98%+ | 1379686-30-2 |
| SR9011 | 99% | 1379686-29-9 |
| Ligandrol/LGD-4033 | 99% | 1165910-22-4 |
| RAD 140 | 99% | 1182367-47-0 |
| S-23 | 1010396-29-8 | |
| Aicar | 99%+ | 2627-69-2 |
| Trenavar | 99%+ | 4642-95-9 |
| Halodrol | 99%+ | ------ |
| Epistane | 99%+ | 4267-80-5 |
| HMG 75iu | 75iu | ------ |
Peptides list
| Adipotide | 5 mg |
| BPC 157 | 5 mg |
| TB 500 | 2 mg |
| TB 500 | 5 mg |
| PT 141 | 10 mg |
| Fragment 176-191 | 2mg |
| Ipamorelin | 2 mg |
| Ipamorelin | 5 mg |
| Melanotan 2 | 10 mg |
| GHRP-2 | 5 mg |
| GHRP-6 | 5 mg |
| CJC 1295 DAC | 2 mg |
| CJC 1295 NO DAC | 2 mg |
| GHK-Cu | 50mg |
| MGF | 2 mg |
| PEG-MGF | 2 mg |
| Epithalon | 10 mg |
| Selank | 5 mg |
| Selank | 20mg |
| Semax | 20mg |
| Sermorelin | 2 mg |
| Ig*F DES | 1 mg |
| Ig*F LR3 | 1 mg |
| HMG 75iu | 75iu |
Pharmaceutical Intermediate
-
Egr25 Linear Guide Rail 2000mm with Slide Block for Conveyor
0.5mm Thick ASTM A623 BS En Dr7 Dr8 Dr9 Stable When Exposed to Heat Tinplate Coil for Food Packaging Materials
Hydraulic Seal 110 *150*15 Tc Oil Seal Auto Parts China Supplier
Smaj8.0A Surface Mousnt Transient Voltage Suppressor
Wear Plate Xar400 Xar450 Xar500 Xar600 Wear Resistant Steel Sheet Hb360 Hb400 Hb450 Hb500 Hb600
Hot Cold Rolled Cheap 4 X 8 FT 4mm 6mm 8mm 10mm Ss 201 304 304L 316 316L 321 310S 430 Mirror Decorative Stainless Steel Sheet Metal Plate for Decoration
Non-Competitive NMDA Antagonists Namenda Memantine HCl Alzheime's Disease Drug Bulk Stock CAS: 41100-52-1
12m Electric Hydraulic Self Propelled Crawler Vertical Scissor Lift for Sale
China Battery Grade Zinc Chloride 98% Zncl2 Prompt Shipment CAS: 7646-85-7
Metal Nameplates DOT Peen Marking/Engraving Machine /Vin Number Marker
304 316 Stainless Steel Thin Hex Nuts Hexagon Jam Nuts
Factory Price Z30 / Z275 Zinc Coated Iron Sheet Galvanized Steel Coil / Sheet / Plate / Roll for Roofing Sheets
High Pressure Centrifugal Fan Blower with Super Wind Chinese Manufacturer
Wholesale Price 50kg Drum Powder Naclo2 Sodium Chlorite for Textile Bleaching
China Manufacture A283gr. C Low Carbon Steel Sheet Plate
Ncsutio DSP CNC Wood Router 1325 Wood Working Engraving Carving Cutting Machine 3.2kw 4.5kw 5.5kw
Highway Safety Blue and Red LED 4 Sets Blinker Warning Solar Traffic Light
1/6 C-Shaped Steel Base Section Steel Angle Bracket Seismic Base
Construction Aerial All Terrain Tracked Electric Hydraulic Scissor Lift
Europe Turkish Bst500s ASTM A615 Grade 60 75 Hrb 400 600 Deformed Rebar Steel
6mm 8mm 10mm 12mm Iron Rebar / Deformed Steel Bar with ASTM A615 Grade 60 for Civil Engineering Construction
Factory Laughing Gas China 470L N2o Nitrous Oxide Gas Cylinder
High Quality SPCC Bright 2.8 T1 Dr7 Food Grade Tinplate Coil for Can Tinplate
Stainless Steel Sectional Modular Water Storage Tank with Steel Tower
Oil Seal Automobile NBR Oil Seal 9828 -01120 Sz311-01006 Tb 140*160*14 Ad1013e0
DIN439 M6 M8 M10 A2-70 Stainless Steel Hex Hexagon Thin Nut Jam Nut
Type Xe-Sc+1 Corrugated Sidewall Endless Rubber Conveyor Belt
for Special Glass 7803-62-5 99.9999% Silane Sih4 Gas
Factory Cost Arc Segment Permanent Magnet for Alternators
European and American Style Punk Jewelry Stainless Steel Crown Lion Head Gold Men's Ring
Helium Gas High Purity 99.9%~99.999%
Customized Stainless Steel Brass Hex Thin Nut Metric Hex Nut
PNEUTEC.IT, 2023